Sciwind Biosciences
- Biotech or pharma, therapeutic R&D
Sciwind is a biotechnology company focused on discovering and developing novel peptide- and antibody-based therapies for metabolic diseases. Leveraging proprietary technology platforms, we are advancing a robust pipeline anchored by our lead asset, Ecnoglutide (XW003), currently in the BLA stage in China. Our portfolio targets GLP-1 and synergistic mechanisms, offering both injectable and oral treatment solutions to deliver sustainable and high quality treatments for patients.
)
)
){kind=logo}
){kind=logo}
){kind=logo}